Matrix metalloproteinases and myocardial infarction

Canadian Journal of Cardiology

Volumn 23, Issue 9, 2007, Pages 727-733

  Phatharajaree, Wannakorn ^a   Phrommintikul, Arintaya ^a,b   Chattipakorn, Nipon ^a,b  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Metalloproteinases; Myocardial infarction; Remodelling

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LOSARTAN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; SITAXSENTAN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACUTE HEART INFARCTION; CELL DAMAGE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE THERAPY; HEART MUSCLE CELL; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34547978884     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70818-8     Document Type: Review

References (58)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
2. McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: A corollary to infarct expansion. Circulation 1986;74:693-702.
3. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
4. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 2001;89:201-10.
5. Rajavashisth TB, Xu XP, Jovinge S, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by proinflammatory mediators. Circulation 1999;99:3103-9.
6. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995;270:5872-6.
7. Lindsey ML. MMP induction and inhibition in myocardial infarction. Heart Fail Rev 2004;9:7-19.
8. Menon B, Singh M, Singh K. Matrix metalloproteinases mediate beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes. Am J Physiol Cell Physiol 2005;289:C168-76.
9. 1 integrin signaling and mitochondrial pathway. Am J Physiol Cell Physiol 2006;290:C254-61.
10. Ovechkin AV, Tyagi N, Rodriguez WE, Hayden MR, Moshal KS, Tyagi SC. Role of matrix metalloptoteinase-9 in endothelial apoptosis in chronic heart failure in mice. J Appl Physiol 2005;99:2398-405.
11. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 1993;53:288-95.
12. Schmidt R, Bultmann A, Ungerer M, et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: Implications in acute myocardial infarction. Circulation 2006;113:834-41.
13. Cao J, Drews M, Lee HM, Conner C, Bahou WF, Zucker S. The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A. J Biol Chem 1998;273:34745-52.
14. Zucker S, Lysik RM, Zarrabi HM, et al. Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment. Ann NY Acad Sci 1994;732:248-62.
15. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27.
16. Kloner RA, Ellis SG, Lange R, Braunwald E. Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation 1983;68:18-15.
17. Vargas SO, Sampson BA, Schoen FJ. Pathologic detection of early myocardial infarction: A critical review of the evolution and usefulness of modern techniques. Mod Pathol 1999;12:635-45.
18. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 2005;115:599-609.
19. Mukherjee R, Brinsa TA, Dowdy KB, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 2003;107:618-25.
20. Zhang P, Yang YJ, Chen X, et al. [Effects of doxycycline on the expression of matrix metalloproteinase and tissue inhibitor of MMP in myocardium after acute myocardial infarction: An animal experiment with rats.] Zhonghua Yi Xue Za Zhi 2004;84:1288-93.
21. Herzog E, Gu AG, Kohmoto T, Burkhoff D, Hochman JS. Early activation of metalloproteinases after experimental myocardial infarction occurs in infarct and non-infarct zones. Cardiovasc Pathol 1998;7:307-12.
22. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995;27:1281-92.
23. Chen J, Tung CH, Allport JR, Chen S, Weissleder R, Huang PL. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 2005;111:1800-5.
24. Wilson EM, Moainie SL, Baskin JM, et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003;107:2857-63.
25. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72.
26. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004;10:328-33.
27. Hirohata S, Kusachi S, Murakami M, et al. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 1997;78:278-84.
28. Eckart RE, Uyehara CF, Shry EA, Furgerson JL, Krasuski RA. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J Interv Cardiol 2004;17:27-31.
29. Wagner DR, Delagardelle C, Ernens I, Rouy D, Vaillant M, Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006;12:66-72.
30. Feldman LJ, Mazighi M, Scheuble A, et al. Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit. Circulation 2001;103:3117-22.
31. Creemers E, Cleutjens J, Smits J, et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol 2000;156:1865-73.
32. Gaertner R, Jacob MP, Prunier F, Angles-Cano E, Mercadier JJ, Michel JB. The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat. J Mol Cell Cardiol 2005;38:193-204.
33. Kawakami R, Saito Y, Kishimoto I, et al. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 2004;110:3306-12.
34. Zhou X, Huang J, Chen J, Su S, Chen R, Gu D. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thromb Haemost 2004;92:867-73.
35. Gao B, Li ZC. [Association between serum matrix metalloproteinase-3 concentration and the promoter 5A/6A polymorphism in patients with coronary heart disease.] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2004;16:536-9.
36. Pollanen PJ, Lehtimaki T, Mikkelsson J, et al. Matrix metalloproreinase3 and 9 gene promoter polymorphisms: Joint action of two loci as a risk factor for coronary artery complicated plaques. Atherosclerosis 2005;180:73-8.
37. Kalela A, Koivu TA, Sisto T, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002;62:337-42.
38. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006;97:175-80.
39. Blankenberg S, Rupprecht HJ, Poirier O, et al; AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
40. Li PJ, Yang XH, Zhang LP, Cao W, Qin J, Yao W. [Clinical significance of soluble selectins and matrix metalloproteinases-9 in patients after successful cardiopulmonary resuscitation.] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2004;16:137-41.
41. Renko J, Kalela A, Jaakkola O, et al. Serum matrix metalloproteinase-9 is elevated in men with a history of myocardial infarction. Scand J Clin Lab Invest 2004;64:255-61.
42. Guo A, Wei L, Shi H, Li X, You L. [Matrix metalloproteinase-1 and coronary atheroslerotic plaque rupture.] Zhonghua Bing Li Xue Za Zhi 2000;29:263-6.
43. Nojiri T, Morita H, Imai Y, et al. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol 2003;92:181-6.
44. Matsunaga T, Abe N, Kameda K, et al. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int J Cardiol 2005;105:203-8.
45. Wehrens XH, Doevendans PA. Cardiac rupture complicating myocardial infarction. Int J Cardiol 2004;95:285-92.
46. Hayashidani S, Tsutsui H, Ikeuchi M, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003;285:H1229-35.
47. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55-62.
48. Creemers EE, Davis JN, Parkhurst AM, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2003;284:H364-71.
49. Jayasankar V, Woo YJ, Bish LT, et al. Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy. Circulation 2004;110:II180-6.
50. Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999;99:3063-70.
51. Yarbrough WM, Mukherjee R, Escobar GP, et al. Selective targeting and timing of matrix metalloproteinase inhibition in postmyocardial infarction remodeling. Circulation 2003;108:1753-9.
52. Podesser BK, Siwik DA, Eberli FR, et al. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol 2001;280:H984-91.
53. 1 attenuates myocardial ischemia-reperfusion injury via inhibition of upregulation of MMP-1. Am J Physiol Heart Circ Physiol 2003;284:H1612-7.
54. Camp TM, Tyagi SC, Aru GM, Hayden MR, Mehta JL, Tyagi SC. Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant 2004;23:729-36.
55. Zhang P, Yang YJ, Chen X, et al. [Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats.] Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005;27:53-61.
56. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004;24:733-8.
57. Papadopoulos DP, Economou EV, Makris TK, et al. Effect of angiotensin-converting enzyme inhibitor on collagenolytic enzyme activity in patients with acute myocardial infarction. Drugs Exp Clin Res 2004;30:55-65.
58. Tziakas DN, Chalikias GK, Parissis JT, et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 2004;94:269-77.